MedTrace Logo

A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of AK120 in Subjects With Atopic Dermatitis

NCT06035354 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 427

Last updated 2025-03-05

No results posted yet for this study

Summary

This is a randomized, double-blind, placebo-controlled, multicenter phase Ib/II clinical study to evaluate the safety, pharmacokinetics and efficacy of AK120 in the treatment of subjects with moderate to severe atopic dermatitis.

Conditions

Interventions

DRUG

AK120

subcutaneous injection once a week

DRUG

AK120

subcutaneous injection once a week

DRUG

Placebo

subcutaneous injection once a week.

DRUG

AK120

subcutaneous injection every 2 weeks.

DRUG

AK120

subcutaneous injection every 2 weeks.

DRUG

AK120

subcutaneous injection every 2 weeks.

DRUG

Placebo

subcutaneous injection every 2 weeks for 16 weeks then crossover to AK120 Regimen 4 and Regimen 5.

DRUG

AK120

subcutaneous injection every 2 weeks

DRUG

AK120

subcutaneous injection every 2 weeks.

DRUG

AK120

subcutaneous injection every 2 weeks.

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-03
Primary Completion
2024-06-21
Completion
2024-06-21

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06035354 on ClinicalTrials.gov